Also, they didn’t experience significantly slower disease progression than those in the interferon beta-1a group over the first several months. This is one more medication for multiple sclerosis, which is of course extremely welcome, but it’s just one in addition to the 11 or 12 drugs we curently have, said Dr. Eugene Lai, a neurologist at Houston Methodist Hospital in Houston, who was not involved in the extensive research. It does decrease the relapse rate, nonetheless it probably doesn’t reach the real primary of the MS disease process, and we still hardly understand exactly how relapse rate and progression are related, Lai added. It’s still not really the definitive treatment for MS however that may stop it. The analysis is published Oct.The consensus guideline was permitted by a research grant from the Susan G. Komen Basis and underwent comprehensive peer review ahead of approval by the SSO Executive Council and ASTRO's Plank of Directors in October 2013. Furthermore, the American Society of Breast Surgeons and the American Culture of Clinical Oncology have both endorsed the guideline. It is available open gain access to on-line as a PDF document at and and you will be published in the March 1, 2014 print problem of the International Journal of Radiation Oncology – Biology – Physics , the state scientific journal of ASTRO; the March 2014 printing problem of Annals of Medical Oncology, the state journal of SSO; and the March 10, 2014 problem of the Journal of Clinical Oncology, the official journal of ASCO.